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Renal uptake of an 18-mer phosphorothioate oligonucleotide
RAINER OBERBAUER, GEORGE F. SCHREINER, and TIMOTHY W. MEYER
Departments of Medicine, Palo Alto VAMC and Stanford University, and CV Therapeutics, Palo Alto, California, USA
Renal uptake of an 18-mer phosphorothioate oligonucleotide. Renal
uptake of a 35S labeled 18-mer phosphorothioate oligodeoxynucleotide
(molecular wt --6,000) was evaluated following intravenous infusion into
rats. The kidneys contained 21 3% of the infused dose at five hours after
infusion and 3 1% of the infused dose at four days after infusion. The
concentration of oligonucleotide was greater in the kidney than in the
liver, spleen, or plasma at both intervals. Urine excretion of oligonucleo-
tide label averaged 17 1%, 35 5%, and 64 3% of the infused dose
at five hours, one day, and four days after infusion. Electrophoresis
(PAGE) showed that oligonucleotide was retained in the kidney as the
intact 18-mer at both five hours and four days after infusion, while full size
oligonueleotide was not found in the urine at either interval. Light
microscopic autoradiography showed that oligonucleotide uptake was
most prominent in the early proximal tubule. Electron microscopic
autoradiography indicated that oligonueleotide was not confined to the
brush border or endocytic-lysosomal pathway. Micropuncture studies
showed that the tubule fluid to plasma concentration ratios of oligonucle-
otide label averaged 7 3% in Bowman's space and 6 2% in the distal
tubule. Despite restriction of filtration by plasma protein binding, as
indicated by the low Bowman's space to plasma concentration ratio, the
calculated tubular reabsorption rate for oligonucleotide was sufficient to
account for the large amount of oligonucleotide found in the kidney after
intravenous infusion. These results indicate that the proximal tubule plays
a prominent role in the disposition of intravenously infused oligonucleo-
tide, and raise the possibility that oligonucleotides could exert antisense
effects in this nephron segment.
It has recently been suggested that oligonucleotides will have
widespread pharmaceutical use [1—4]. The major promise of
oligonucleotide therapy is specificity: theoretically, it should be
possible to produce an antisense oligonucleotide which will inter-
fere with the expression of any gene of known sequence. One
difficulty to be overcome in the development of antisense therapy
is rapid degradation of oligodeoxynucleotides. Several structural
modifications, including most frequently modification of the
phosphodiester backbone, have been employed to limit oligonu-
cleotide degradation. To date, success has been best with phos-
phorothioate oligonucleotides, in which one oxygen of each
internueleotide linkage is replaced by sulfur [3—5]. Therapeutic
efficacy has been achieved with a variety of antisense phosphoro-
thioate oligonucleotides in vitro and in vivo, and clinical trials have
been initiated using agents in this class. A second major difficulty
in the development of antisense therapy is limited cellular uptake
of oligonucleotides. A number of strategies, including combina-
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tion of antisense with lipids and viral proteins, have been em-
ployed to facilitate antisense uptake [4, 6]. With systemic infusion
of naked antisense in vivo, high doses may be required to achieve
concentrations similar to those successfully employed in vitro, and
even high dose infusion may not result in adequate antisense
uptake by target tissues. Recent kinetic studies have shown that
when phosphorothioate oligonucleotides are infused systemically,
a major portion of the dose infused is taken up by the kidney
[79]. This finding suggests both that the kidney plays a significant
role in the clearance of oligonucleotides and that high levels of
oligonucleotides may be delivered to at least some types of kidney
cells by systemic infusion. The current study was designed to
further assess the renal kinetics of a systemically infused 18-mer
phosphorothioate oligonucleotide. In particular, we sought to
localize oligonucleotide uptake within the kidney and determine
whether oligonucleotide can remain intact in kidney cells for
several days following a single systemic infusion.
Methods
Oligonucleotide
Studies were carried out with an 18-mer phosphorothioate
nucleotide of molecular weight 5722 Da and sequence 5'-ATC-
TTC-CAT-AGT-TAG-TCA-3'. This sequence is antisense against
human cdc2 starting at base 118 of the eDNA sequence published
by Lee and Nurse [10]. To facilitate kinetic studies, the oligonu-
cleotide was internally radiolabeled with 35S during synthesis to an
activity of 1250 j.rCi/rmol.
Clearance studies
The plasma clearance of labeled oligonucleotide was assessed
in two groups of male Sprague-Dawley rats weighing 370 to 460
grams. Rats were anesthetized with lnactin (100 mg/kg body wt
i.p.) and placed on a temperature regulated table. A PE-50
catheter was inserted into the left femoral artery and used for
subsequent blood sampling and estimation of mean arterial
pressure. After tracheotomy, PE-50 catheters were inserted into
the right and left jugular veins for infusion of rat plasma, normal
saline, oligonucleotide, and inulin. Plasma was infused in an
amount equal to 1% body wt over 45 minutes, followed by a
reduction of the infusion rate to 0.4 mI/hr for the duration of the
study. Normal saline was infused at 1.2 mI/hr throughout the
study. The left ureter was exposed through a midline abdominal
incision and a PE 10 catheter was installed for urine collection.
In both groups of rats a constant infusion of oligonucleotide was
begun after 90 minutes and continued for 150 minutes. The first
group of rats (N = 5) received labeled oligonucleotide at the rate
of 119 ng/min. The second group of rats (N = 4) received the
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same amount of labeled oligonucleotide along with addition of
unlabeled oligonucleotide to achieve a total oligonucleotide infu-
sion rate of 17.5 g/min. Blood samples were obtained every thirty
minutes over five hours, beginning at the initiation of oligonucle-
otide infusion and continuing for 150 minutes after the cessation
of oligonucleotide infusion. Beginning at approximately 120 min-
utes, 10% inulin (Iso-tex Diagnostics, Friendswood, TX, USA)
was infused with the normal saline and 30-minute urine samples
were obtained between blood samples for measurement of inulin
clearance.
Distribution of intravenously infused oligonucleotide
At the close of clearance studies, kidneys and samples of liver,
plasma, lung, and spleen were obtained. Tissue content of 35S was
determined by scintillation counting of tissue samples homoge-
nized in water (--100 mg tissue per ml). Quenching experiments
showed that the counting efficiency in 20 pA samples of tissue
homogenates was greater than 90%. Urinary excretion of 35S was
also assessed by scintillation counting.
Studies were carried out over four days in a separate group of
rats to assess the tissue distribution of oligonucleotide at a later
interval after intravenous infusion. Male Sprague-Dawley rats
weighing 300 to 390 grams were anesthetized briefly with Brevital,
50 mg/kg, i.p. and a catheter was installed in the left jugular vein.
After infusion of 86 jtg of labeled oligonucleotide over 80 minutes
the catheter was removed and the rats were placed in metabolic
cages. Urine was collected for four days and the rats were then
sacrificed and tissue distribution of 35S was determined as de-
scribed above.
The extent of oligonucleotide degradation in tissue and urine
samples was assessed by PAGE. Weighed tissue samples were
homogenized in buffer (0.5% SDS/10 ms NaCI/20 mM TRIS, pH
7.6, 10 mM EDTA) and treated with Proteinase K (2 mg/ml) for
two hours at 37°C. Proteinase digests were extracted twice with
phenol/chloroform and once with chloroform. The final extracts
were concentrated on microfilter discs with a cut-off of 3,000 Da
(Microcon 3, Amicon, Beverly, MA, USA) before application to
20% polyacrylamide gels containing 7 M urea. Following electro-
phoresis, the gels were fixed in 10% acetic acid/10% methanol,
dried, and subjected to autoradiography.
Micropuncture studies
Glomerular filtration and tubular handling of intravenously
infused oligonucleotide was further assessed by micropuncture in
Munich Wistar rats (N = 4). Male rats weighing 300 to 350 grams
were prepared for renal function studies as described above,
except that the oligonucleotide infusion was begun after 70
minutes and continued at a rate of 2.4 jig/mm for 210 minutes.
Timed (4 to 7 mm) tubule fluid samples were obtained during two
to three clearance periods beginning 40 minutes after initiation of
oligonucleotide infusion. Samples were obtained from Bowman's
space (3 to 5 samples per rat) and the distal tubule (2 to 5 samples
per rat). Distal tubule segments were identified by preliminary
injection of 1% lissamine green through pipettes of —4 j.t outer
diameter. The volume of tubule fluid samples was determined by
injecting the samples into light mineral oil. The diameter of the
droplet formed by each sample was assessed by light microscopy
and the volume of the droplet then calculated by assuming its
shape was spherical. Following volume determination, the tubule
fluid droplets were transferred to scintillation vials and their 35S
content was assessed. The accuracy of the volume determinations
was confirmed by the finding of 97 3% of predicted counts in
measured droplets of a standard solution of labeled oligonucleo-
tide. The total load of label filtered over the course of the 210
minutes oligonucleotide infusion in each rat was obtained as the
area under the curve:
[label]ptasma GFR TF/P Bowman's space
where values for the concentration of label in the plasma,
[label]piasma, were obtained by curve fitting from plasma levels
measured at 30 to 50 minute intervals.
Autoradiographic studies
Localization of oligonucleotides within the kidney was assessed
by autoradiography. Kidneys were harvested at three hours after
oligonucleotide infusion in two rats and at four days after
oligonucleotide infusion in three rats. Labeled oligonucleotide
was infused as described above except that the dose infused into
rats studied at four days was increased to 326 jig. Kidneys were
fixed by retrograde aortic perfusion with 1.25% glutaraldehyde in
0.1 M cacodylate buffer (pH 7.4). For light microscopic autora-
diography, coronal slices of kidney tissue were embedded in
paraffin and 5 /.tM sections were mounted on slides and coated
with emulsion (NTB2, Kodak, Rochester, NY, USA). After three
weeks of exposure, the slides were developed, dried, and stained
with hemotoxylin and eosin. A semiquantitative scoring system
was used to compare uptake of labeled oligonucleotide in very
early and later proximal nephron segments in two sections from
each rat. Individual tubule profiles were scored 0 (no grains above
background) to 3+ (dense grains). The average score in sections
of very early segments of the proximal nephron, identified by
visible transformation of the tubule into the parietal epithelium of
a glomerulus, were compared with the average scores in sections
of the proximal nephron selected at random by positioning the
microscope stage without looking at the specimen. For electron
microscopic autoradiography, small blocks of cortical tissue were
embedded in Epon and 60 to 100 flM sections were mounted on
grids and coated with emulsion (1L4, Ilford, Essex, UK). After
three weeks of exposure, sections were developed, fixed and
counterstained with lead citrate and uranyl acetate.
Results
The tissue distribution of 35 following intravenous infusion of
labeled oligonucleotide is summarized in Table 1. In rats sacri-
ficed five hours after infusion of 16 jig oligonucleotide, the largest
portion of the infused label was found in the kidney. A slightly
lesser amount was found in the liver. Only a small amount of the
infused label remained in the plasma while an amount similar to
that found in the kidneys and liver was excreted in the urine.
Expression of tissue content of infused label per gram organ
weight revealed that the concentration of label in the kidney was
more than twentyfold greater that the concentration of label in
the plasma and more than fivefold greater than the concentration
of label in the liver. The concentration of label in lung and spleen
was less than that in the plasma (data not shown). Prominent
uptake of label in the kidney was again observed in rats sacrificed
five hours after infusion of 2414 jig of oligonucleotide. The
fraction of infused label found in the kidney and liver in these
animals was less than in animals which received a much smaller
nfr
.
.
$l
K3K96P3 U3 UN S
1228 Oberbauer et a!: Renal oligonucleotide uptake
Table 1. Distribution of intravenously infused 35S label
5 hours 4 days
pg infused 4 jig infused18 241 86 jig infusedN=5 N=4 N=4
% dose % dose % dose
% dose per gram % dose per gram % dose per gram
Kidney 21.2 2.7 7.4 0.8 11.2 0.9 3.8 0.3 2.9 0.5 1.3 0.2
Liver 17.4 1.6 1.3 0.3 12.4 1.9 0.9 0.2 3.9 0.2 0.3 0.1
Plasma 3.2 0.5 0.3 0.1 5.2 0.6 0.4 0.1 <0.1 <0.1
Urine 17.6 0.9 17.0 1.9 63.5 2.7
Data are mean so.
Fig. 1. PAGE analysis of kidney tissue, plasma, and urine after intravenous
oligonucleotide infusion. Intact oligonucloetide with size equal to that in
the infusate (S) was found in the kidney at three hours and 96 hours (K3
and K96) and in the plasma at three hours (P3). In contrast, intact
oligonucleotide was not detected in the urine at either interval (U3 and
U96). Plasma concentration of label was too low for PAGE analysis at 96
hours.
amount of oligonucleotide, but the concentration of label in the
kidney again greatly exceeded that in the liver and plasma. The
fraction of label excreted in the urine over five hours was similar
when rats received 2414 jig of oligonucleotide as when they
received 18 jig of oligonucleotide. Studies performed at four days
after oligonucleotide infusion showed that significant portions of
label remained in the kidney and liver while no label was
detectable in the plasma. The concentration of label in the kidney
again exceeded that in the liver. Over four days, the majority of
the infused label was excreted in the urine. Of the amount infused,
43 5% was excreted on day 1, 12 5%was excreted on day 2,
6 4% was excreted on day 3, and 3 1% was excreted on day
4.
Results of PAGE analysis of kidney tissue, plasma, and urine
obtained three hours after oligonucleotide infusion and of kidney
tissue and urine obtained four days after oligonucleotide infusion
are illustrated in Figure 1. The appearance of label in a single
band with size equivalent to the infused 18-mer indicated that
oligonucleotide taken up by the kidney remained largely intact at
0
0 60 120 180 240 300
Time, minutes
Fig. 2. Plasma concentration of 35S oligonucleotide label in rats receiving a
constant infusion of oligonucleotideover 150 minutes, illustrating rapid
plasma clearance following discontinuation of the infusion. Plasma levels of
labeled oligonucleotide were only slightly higher when labeled oligonucle-
otide was infused with cold oligonucleotide (0, total infusion rate 17.5
jig/mm) than when the same amount of labeled oligonucleotide was
infused alone (LII, infusion rate 119 ng/min; * P < 0.05).
both three hours and four days and that oligonucleotide in the
plasma remained largely intact at three hours. In contrast, intact
oligonucleotide was not found in the urine at either interval.
Similar results were obtained in four rats sacrificed at three hours
and two rats sacrificed at four days.
Plasma levels of labeled oligonucleotide observed during and
after constant infusion of oligonucleotide for 150 minutes are
depicted in Figure 2. Oligonucleotide concentration increased
rapidly over the first 30 minutes of infusion and appeared to be
approaching a plateau at 150 minutes. The addition of a large
excess of cold oligonucleotide resulted in plasma levels of labeled
oligonucleotide that were only slightly greater than those ob-
served during infusion of labeled oligonucleotide alone. The peak
plasma oligonucleotide concentration achieved during infusion of
labeled oligonucleotide alone, calculated from the specific activ-
ity, was 37 2 nM. Presuming no difference in the clearance of
cold and labeled oligonucleotide, the peak plasma oligonucleotide
concentration achieved during their combined infusion was 6.9
0.2 jiM. Infusion of an 147-fold greater quantity of oligonucleotide
thus resulted in an 186-fold increase in the plasma oligonucleotide
concentration, indicating that plasma clearance was reduced only
slightly as oligonucleotide concentration increased. Consistent
1,250
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Table 2. Summaiy of micropuncture studies
Tubule fluid
flow rate
nI/mm
[label],hlC flaid
[labelipiasma
Fractional
delivery
%
Bowman's space 50 2 0.07 0.03 (100)
Distal tubule 18 2 0.06 0.02 34 19k'
Urine 3.20 0.42 21 8
Data are: mean SD.
aP < 0.05 vs. Bowman's space
with this conclusion, plasma oligonucleotide clearance rates over
the first 30 minutes after discontinuation of the infusion were 0.32
0.01 ml/min/400 g in the rats receiving only labeled oligonucle-
otide and 0.26 0.04 ml/min/400 g in rats receiving an excess of
cold oligonucleotide along with labeled oligonucleotide (P <
0.05). These mean values for plasma oligonucleotide clearance
rate were much less than the corresponding mean values for GFR
(1.95 0.18 ml/min/400 g and 2.13 0.14 ml/min/400 g) but
greater than mean values for clearance of plasma oligonucleotide
label into the urine (0.07 0.02 ml/min/400 g and 0.04 0.01
ml/min/400 g). Examination of a logarithmic plot of oligonucleo-
tide concentration suggested that oligonucleotide clearance was
reduced by 120 minutes following discontinuation of the low dose
infusion, but the experiments were not carried out long enough to
calculate accurate plasma clearance rates at this interval.
Micropuncture studies were performed to determine whether
intravenously infused oligonucleotide was filtered by the glomer-
ulus and then reabsorbed. Values for physiologic parameters
including GFR (1.50 0.12 ml/min), mean arterial pressure (110
5 mm Hg), and hematocrit (44 2) in rats subjected to
micropuncture were similar to values previously obtained in
normal animals [11]. Results of micropuncture measurements are
summarized in Table 2. SNGFR, measured as the rate of fluid
collection from Bowman's space, averaged 50 2 nl/min and the
tubule fluid to plasma concentration ratio of label in Bowman's
space averaged 0.07 0.03. Distal tubule fluid delivery averaged
18 2 nI/mm and the tubule fluid to plasma concentration ratio
of label in the distal tubule averaged 0.06 0.02, while the urine
to plasma concentration ratio of label averaged 3.20 0.42.
Taking the delivery of label to Bowman's space as 100%, values
for the fractional delivery of label averaged 34 19% in the distal
nephron and 21 8% in the urine. Delivery of filtered label into
the urine was not significantly less than delivery of filtered label to
the distal tubule, so that reabsorption of label beyond the distal
micropuncture site was not detected. The total delivery of the
intravenously infused label to Bowman's space during the 210-
minute infusion period, calculated by multiplying the Bowman's
space to plasma concentration ratio by the average plasma
concentration and the GFR, was estimated to be 58 26% of the
total amount infused. This value exceeded the combined portion
of the infused label returned in the kidneys and excreted in the
urine, which averaged 23 4% in rats subjected to micropunc-
ture.
Results of autoradiographic studies are illustrated in Figures 3
and 4. At three hours after oligonucleotide infusion, light micro-
scopic autoradiography revealed prominent uptake of oligonucle-
otide in proximal tubules (Fig. 3A) while deposition of oligonu-
cleotide was not detected in glomeruli, distal tubules, or in the
medulla (Fig. 3B). Between 70 and 80% of proximal tubule cross
sections were scored as exhibiting grain density above back-
ground. Of note, however, the pattern of oligonucleotide uptake
in proximal tubules was uneven. Semiquantitative scoring re-
vealed that uptake of oligonucleotide was more prominent in the
earliest portion of the tubule, as identified by visible transforma-
tion of the tubular epithelium into Bowman's capsule, than in
randomly selected proximal tubule profiles (mean score, 2.2 0.8
vs. 1.3 0.9, P < 0.05). The pattern of oligonucleotide uptake, as
assessed by light microscopic autoradiography, remained the same
at four days after oligonucleotide infusion (Figs. 3 C, D). Signif-
icant uptake was again observed only in the proximal tubules, and
uptake was greater in the earliest portion of the tubule than in
randomly selected tubule profiles (mean score, 2.2 0.9 vs. 1.3
1.0, P < 0.05). Electron microscopic studies revealed that within
three hours after infusion, oligonucleotide was taken up into
proximal tubule cells and not simply bound to brush border (Fig.
4). Oligonucleotide distribution did not appear to be confined
exclusively to any compartment within proximal tubule cells, and
was not notably different in electron micrographs prepared from
tissue obtained at three hours and at four days after infusion.
Discussion
The current study demonstrated a high concentration of a
phosphorothioate oligonucleotide within the kidney at three
hours following intravenous infusion. This finding is consistent
with results of previous studies of phosphorothioate oligonucleo-
tide pharmacokinetics. Agrawal, Temsamani and Tang [7] evalu-
ated tissue distribution of a 35S labeled 20-mer phosphorothioate
following bolus intravenous and intraperitoneal administration in
mice, and Cossum and associates [8, 9] evaluated tissue distribu-
tion of a different 14C labeled 20-mer phosphorothioate following
bolus intravenous and intraperitoneal administration in rats. In
each study, concentration of oligonucleotide label in the kidney
exceeded that in liver, which was the organ exhibiting the next
highest concentration, by several fold. Cossum et al [9] calculated
that the kidney contained 16% of the total oligonucleotide dose at
four hours after intravenous infusion in rats. As summarized in
Table 1, similar values for kidney content of oligonucleotide were
obtained in the current study.
A lesser but still significant fraction of the infused dose of
oligonucleotide remained present within the kidney at four days
following oligonucleotide administration. Gel electrophoresis
showed, moreover, that the majority of the oligonucleotide
present in the kidney at both three hours and four days after
administration was in the form of the intact 18-mer. The concen-
tration of oligonucleotides in kidney cells was not measured in the
current study, but could be estimated from the fraction of the
infused dose retained in the kidney. Kidney oligonucloetide
content in rats receiving 2414 g of oligonucleotide averaged 92
7 .tgIg kidney at five hours, equivalent to approximately 10 jLM.
Antisense effects have frequently been observed at similar or
lesser concentrations of oligonucleotide [4]. These findings thus
suggest that intravenously infused oligonucleotides could exert
antisense activity in the kidney if they are taken up into an
appropriate cellular compartment. The mechanism responsible
for reduction of kidney oligonucleotide content between three
hours and four days after oligonucleotide administration was not
identified in the current study. Studies in cultured cells have
shown, however, that oligonucleotides can both be released from
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Fig. 3. 4 utoradiographs illustrating intra renal localization of label at three hours (A and B, cortex and medulla) and four days (C and D, cortex and medulla)
after intravenous infusion. Uptake at both intervals was confined to proximal tubules with staining not observed in glomeruli, distal tubules, or medullary
structures (II & E, print magnification x250).
cells intact and he degraded intracellularly 12—14j. Degradation cleotides of reduced chain length were not detected in the kidney
has generally been thought to begin with cleavage of internucle- at either three hours or four days after administration in the
otide bonds, resulting in the formation of oligonucleotides of current study. This finding, does not, however, rule out a contri-
reduced chain length and ultimately of free nucleotides. Oligonu- bution of intracellular degradation to the reduction in intrarenal
La
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Fig. 4. Electron microscopic autoradiograph illustrating uptake of label in the proximal tubule after three hours of intravenous infusion. Localization to a
specific cellular compartment could not be identified (print magnification X5250).
oligonucleotide content observed with time. Oligonucleotides of
reduced chain length could both have a variety of sizes and be
retained for a limited time in the kidney, making them difficult to
detect by gel electrophoresis. It should be noted that Agrawal et
al [7] observed an electrophoretic pattern suggestive not only of
degradation but also of oligonucleotide chain lengthening in the
kidney at 24 hours after oligonucleotide administration in mice. In
contrast, Cossum et al [9] observed no evidence of chain length-
ening but did detect approximately 50% degradation of oligonu-
cleotide in the kidney after four days, a finding that they related to
incomplete replacement of phosphate by phosphorothioate inter-
nucleotide linkages in the oligonucleotide used in their study.
While intact oligonucleotide was found in the kidney, no intact
oligonucleotide was found in the urine in the current study. This
finding is in agreement with the observation of Cossum et al [9] in
rats but different from the finding of Agrawal et al [7] in mice. It
is possible that the infusion of a large amount of oligonucleotide
(30 mg/kg) as an intravenous bolos contributed to appearance of
intact oligonucleo tide in the urine in the studies of Agrawal et a!
[7]. The current study does not reveal whether excretion of label
in the urine was the result of oligonucleotide degradation in the
kidney, or whether oligonucleotide was degraded in other tissues
and labeled degradation products then excreted by the kidney. An
index of the contribution of the kidney to total plasma oligonu-
cleotide clearance, however, can be obtained by adding the
portion of label found in the kidney to the portion of label found
in the urine. In rats studied over five hours, the kidney and urine
together contained 39 3% of the infused dose when 18 xg was
administered and 28 3% of the infused dose when 2414 xg was
administered. These findings indicate that, while the portion of
the infused label found in kidney tissue and urine was large, the
kidneys were not solely responsible for the clearance of intrave-
nously infused oligonucleotide.
Kinetic studies carried out over five hours also showed that the
plasma oligonucleotide clearance rate was considerably less than
the GFR. This finding established that the oligonucleotide in-
fused, which had a molecular weight of 5722 Da, either was not
freely filtered at the glomerulus or was extensively reabsorbed in
the nephron. Micropuncture studies revealed that the concentra-
tion of oligonucleotide label in Bowman's space averaged only 7
3% of that in plasma, indicating that glomerular filtration of
oligonucleotide was restricted. Binding of oligonucleotides to
plasma proteins presumably accounts for restricted filtration of
oligonucleotides by the glomerulus. In support of this presump-
tion Cossum et al [9] cite unpublished studies in which binding of
a 20-mer phosphorothioate oligonucleotide to albumin and a2-
macroglobulin was demonstrated by HPLC. It should be empha-
sized that the calculated delivery of oligonucleotide into the
nephron, though limited by plasma protein binding, exceeded the
amount of oligonucleotide label retained in the kidney and
excreted in the urinein the current study. This finding indicates
that filtered oligonucleotide label was reabsorbed into the circu-
lation as well as retained by kidney cells. Micropuncture studies
indicated that reabsorption of label was largely accomplished
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prior to the accessible distal nephron. It should be noted that
reabsorption of label could have represented reabsorption of
oligonucleotide degradation products as well as reabsorption of
intact oligonucleotide. Because the amount of radiolabel in tubule
fluid samples was very small, electrophoretic sizing of labeled
compounds in tubule fluid could not be performed. Rates of
filtration and reabsorption of label measured in the current study
therefore provide only upper bounds for the rates of filtration and
reabsorption of intact phosphorothioate oligonucleotide.
Light microscopic autoradiography showed that the intact
oligonucleotide retained in the kidney was localized in the prox-
imal tubule. These studies showed, moreover, that retention of
oligonucleotide was most prominent in the early portion of the
tubule. Electron microscopy showed that oligonucleotide retained
by the kidney was taken up by proximal tubule cells and not
merely adherent to the brush border or other portions of the cell
membrane. These studies are consistent with the hypothesis that
intact oligonucleotides filtered by the glomerulus are taken up
from the tubule lumen into proximal tubule cells, Molecules in the
size range of oligonucleotides, including peptide hormones and
small proteins, are known to be handled by the kidney in this
manner [15—17]. Such peptide molecules have been shown to be
taken up into the proximal tubule by receptor mediated endocy-
tosis and then degraded in lysosomes. The mechanisms of oligo-
nucleotide uptake by the proximal tubule remains to be identified.
Studies in cultured cells suggested that there are oligonucleotide
binding proteins on the cell surface and that oligonucleotides
introduced into the culture media enter lysosomes following
uptake into cells [12, 13, 18—20]. It is possible, however, that
phosphorothioate oligonucleotides taken up into cells are not
confined to lysosomes and related organelles. Phosphorothioate
oligonucleotides are resistant to enzymatic degradation, and may
escape from the endocytic-lysosomal pathway [13, 21]. In addi-
tion, some studies have suggested that the endocytic pathway is
not the only means of phosphorothioate oligonucleotide entry
into cells [13, 18, 22]. Knowledge of the cellular localization of
oligonucleotides might help predict whether intravenously infused
oligonucleotides could block gene expression in the proximal
tubule. Electron microscopic autoradiograms made in the current
study suggested that oligonucleotides taken up in the proximal
tubule were not localized exclusively within endocytic vesicles and
lysosomes. Results showed, moreover, that a high concentration
of oligonucleotide was achieved in the proximal tubule and that a
major portion of the oligonucleotide taken up by the proximal
tubule remained intact over four days. Further studies will be
required to determine whether oligonucleotide taken up by the
proximal tubule following intravenous infusion can exert any
antisense effect.
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